On January 26th, the application for the clinical trial of HSK29116 powder declared by Sichuan Haisco Pharmaceutical Co., Ltd. was accepted by the State Food and Drug Administration. HSK29116 is an oralRead More…
26Feb/21
31Jan/21
Protein Degrader–Opportunities and Challenges
Protein Degrader is a novel technique that induces targeted protein degradation by the ubiquitin-proteasome system (UPS). Different from the traditional occupation-driven pharmacological principles, event-driven Protein Degrader technology has many advantages, such asRead More…
31Jan/21
A Deeper Look into Protein Degrader Technology
Over the past decade, major changes have taken place in the field of drug targets. Although traditional targets (such as kinases and G-protein-coupled receptors) are still the main stream, the focus isRead More…
17Dec/20
New Protein Degrader Interim Data Released—Potential ARV-471 Won Arvinas Doubled Shares
On December 14, 2020, Arvinas released the latest clinical data of ARV-471 and ARV-110, which showed strong therapeutic potential. As soon as the news was released, Arvinas’s share price doubled, with aRead More…
30Nov/20
Focus on Protein Degrader—Target Summary from 2001 to 2019
Protein Degrader, of which the full name is proteolysis-targeting chimera, looks like a dumbbell and mainly consists of a linker, a ligand of interest protein, and a ligand recruiting E3 ubiquitin ligase.Read More…
13Oct/20
Basic Research Progress of Protein Degrader in Hematological Diseases-Part Two
In addition to the T-cell Lymphoma,T-cell Acute Lymphoblastic Leukaemia mentioned in our previous article, there are also related studies of protac in other blood diseases. Next, let’s analyze the research of protacRead More…
13Oct/20
Basic Research Progress of Protein Degrader in Hematological Diseases-Part one
Proteolysis targeted chimera (Protein Degrader) is a rapidly developed technology in recent years, which provides the possibility for many undruggable targets, and has become the focus of protein drug researchers. Hematologic malignanciesRead More…
02Sep/20
Advantages and Challenges of Protein Degrader Technology in Drug Discovery
In recent years, targeted protein degradation chimera (Protein Degrader) as a novel way to induce protein degradation has become a new drug discovery strategy. Compared with traditional protein inhibitor drugs, it hasRead More…
21Aug/20
Ocogene: Novel Anticancer Therapeutics-Protein Degrader
Protein Degraders is a novel technique in protein drug research field. Unlike traditional protein inhibitors, Protein Degraders are potential to target undruggable protein. Therefore, it has become a potential cancer therapy strategy.Read More…
13Jul/20
Protein Degrader: STAT3 specific small molecule degradant inhibits tumor growth
Signal transducer and activator of transcription 3 (STAT3) is a member of the STAT family, which responds to a variety of cytokines, growth factors and other signals and activates the expression ofRead More…